Globus Medical Inc. (NYSE:GMED) is one of the best medical technology stocks to invest in. On January 30, Needham upgraded its rating on Globus Medical Inc. (NYSE:GMED) from Hold to Buy and set the price target at $112. The upgrade followed Globus’s preliminary fourth-quarter revenue announcement, which Needham viewed as a positive signal for the company’s financial performance.
Needham’s analysis identified expanding EBITDA margins, including an estimated 20% EBITDA margin for Nevro, as a driver of improved earnings expectations for fiscal 2026. The firm expects margin expansion to potentially lift Globus’s earnings per share guidance by a high-single to low-double digit percentage, according to its internal assessment.
Alongside margins, Needham noted the possibility of improving organic revenue growth. The analysts believe this could lead to upside relative to Globus’s existing revenue guidance.
Separately, on January 26, TD Cowen initiated coverage on Globus with a Buy rating and set a $110 per share price target. TD Cowen acknowledged that Globus had faced significant negative sentiment, yet the analysts see potential for further outperformance. This will happen if investors continue to appreciate Globus’s longer-term earnings prospects, the analysts noted.
TD Cowen pointed out some of the areas where Globus still has opportunities for growth; these are progress within its Nevro business segment, expansion into international markets, and enabling technologies. Another supportive context that the firm pointed to is Globus’s historical share performance and financial strength.
Globus Medical Inc. (NYSE:GMED) develops and commercializes medical devices and technologies for musculoskeletal disorders. Its portfolio includes implantable devices, biologics, and surgical instruments used in spinal, orthopedic trauma, and joint reconstruction procedures.
While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Foreign Stocks to Buy Right Now and 11 Best AI Penny Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
-1024x768.jpg "Red Snapper Used as Cudgel by Fed Judge")
